[Creutzfeldt-Jakob disease].
Nanri
Yusuke
Y
Department of Internal Medicine, Saga Medical School.
Kuroda
Yasuo
Y
D000962:Antimalarials / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D001921:Brain / Q000378:metabolism / Q000473:pathology; D002746:Chlorpromazine / Q000627:therapeutic use; D007562:Creutzfeldt-Jakob Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D006801:Humans; D008279:Magnetic Resonance Imaging; D010751:Phosphopyruvate Hydratase / Q000134:cerebrospinal fluid; D011328:Prions / Q000032:analysis; D011796:Quinacrine / Q000627:therapeutic use
D000962:Antimalarials; D014150:Antipsychotic Agents; D015415:Biomarkers; D011328:Prions; D010751:Phosphopyruvate Hydratase; D011796:Quinacrine; D002746:Chlorpromazine